Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly approach market entry. As leading […]
Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering
New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience. EXTON, PA – October 22, 2025 — Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market Dynamix™: Hemophilia (US) 2025 and the accompanying Launch […]
Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights
Inaugural coverage will include multiple myeloma, myelodysplastic syndrome and B-cell malignancies (large B-cell lymphoma and chronic lymphocytic leukemia). EXTON, PA., October 15, 2025 – Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, today announced the expansion of its hematology franchise to include […]
Physicians Signal Cautious Enthusiasm for Gene Therapy Across Hematology, But Adoption Remains Selective
New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and hemophilia. October 2, 2025 [Exton, PA] – According to the newly released Special Topix™: Adoption and Impact of Gene Therapy in Hematology, physicians across sickle cell disease […]
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
Ultomiris (AZ/Alexion) and Empaveli (Appellis) identified as driving greater PNH treatment flexibility and individualized care Exton, PA, September 26, 2025 – Spherix Global Insights today announced the latest quarterly update to its RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) service, revealing how patient requests and physician perspectives are reshaping the treatment landscape. This update highlights both the growing influence […]
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics’ Casgevy holding a competitive edge over bluebird bio’s Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, August 14, 2025 — As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology […]
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, August 6, 2025 — According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the […]
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights
Hematologists are poised to jump on new market entrants once available, as high unmet need and frustration with current treatment standards persist in w-AIHA. EXTON, PA, July 29, 2025— According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune hemolytic anemia (w-AIHA) continue to face clinical complexity, […]
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as well as continued use of Alexion’s Soliris and Ultomiris and Apellis’ Empaveli. EXTON, PA, July 17, 2025 – In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global Insights explores the nuanced dynamics […]
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), pozelimab-cemdisiran (Regeneron/Alnylam), and ruxaprubart (NovelMed). EXTON, PA, July 8, 2025 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it is most […]
